Industry News
Pharmaceutical Industry News
Drug repackager Loxha recalls OTC laxative contaminated with microbes
Drug repackager Loxha recalls OTC laxative contaminated with microbes jkeenan Thu, 01/13/2022 - 09:02
JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn’t plan to stop there, exec says
JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says esagonowsky Thu, 01/13/2022 - 08:39
La melatonina no es una pastilla para dormir. Te explicamos cómo funciona
La “hormona vampiro” puede actuar como una dosis de puesta de sol, al engañar a tu cuerpo para que sienta que es hora de dormir.
Genentech, American Cancer Society flash back to the ’70s in PSA to destigmatize lung cancer, encourage screenings
Genentech, American Cancer Society flash back to the '70s in PSA to destigmatize lung cancer, encourage screenings nmissakian Wed, 01/12/2022 - 15:37
AstraZeneca sells another half-million doses of its COVID-19 antibody combo to the US
AstraZeneca sells another half-million doses of its COVID-19 antibody combo to the US fkansteiner Wed, 01/12/2022 - 14:39
Performance Cell picked up by private equity firm, rebrands as Cellipont Bioservices
Performance Cell picked up by private equity firm, rebrands as Cellipont Bioservices jkeenan Wed, 01/12/2022 - 08:36
JPM22, Day 3: Eli Lilly weighs dual branding for diabetes hopeful tirzepatide
JPM22, Day 3: Eli Lilly weighs dual branding for diabetes hopeful tirzepatide fkansteiner Wed, 01/12/2022 - 08:12
JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch
JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch fkansteiner Wed, 01/12/2022 - 08:12
UPDATED: JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch
UPDATED: JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch fkansteiner Wed, 01/12/2022 - 08:12
Pfizer offers a soft sell but with a strong message on vaccines in first COVID ad
Pfizer offers a soft sell but with a strong message on vaccines in first COVID ad sharon.coey Wed, 01/12/2022 - 08:05
Pfizer offers a soft sell with a strong message on vaccines in first COVID ad
Pfizer offers a soft sell with a strong message on vaccines in first COVID ad sharon.coey Wed, 01/12/2022 - 08:05
For Biogen’s Aduhelm, narrow coverage from CMS ‘could effectively spell the end’: analyst
For Biogen's Aduhelm, narrow coverage from CMS 'could effectively spell the end': analyst aliu Wed, 01/12/2022 - 07:18
JPM 2022: Eli Lilly gears up for Alzheimer’s-diabetes juggling act as 2 key FDA decisions loom
JPM 2022: Eli Lilly gears up for Alzheimer's-diabetes juggling act as 2 key FDA decisions loom fkansteiner Wed, 01/12/2022 - 06:53
Pfizer takes the ax to US sales reps amid virtual push
Pfizer takes the ax to US sales reps amid virtual push badams Wed, 01/12/2022 - 05:39
JPM 2022: Eli Lilly CEO mulls using Novo’s double-branding trick on tirzepatide—one obesity, one diabetes
JPM 2022: Eli Lilly CEO mulls using Novo's double-branding trick on tirzepatide—one obesity, one diabetes badams Wed, 01/12/2022 - 03:07
Medicare Proposes to Sharply Limit Coverage of the Alzheimer’s Drug Aduhelm
If the preliminary decision is finalized this spring, it would restrict coverage to patients in randomized clinical trials.
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B kdunleavy Tue, 01/11/2022 - 17:56
JPM 2022: J&J, Legend hope to avoid supply challenges that have ailed Bristol Myers’ Abecma as cilta-cel nears FDA nod
JPM 2022: J&J, Legend hope to avoid supply challenges that have ailed Bristol Myers' Abecma as cilta-cel nears FDA nod aarmstrong Tue, 01/11/2022 - 15:23
JPM 2022: Sanofi has designs on creating Big Pharma’s ‘strongest’ immunology franchise, CFO says
JPM 2022: Sanofi has designs on creating Big Pharma's 'strongest' immunology franchise, CFO says esagonowsky Tue, 01/11/2022 - 15:04
JPM 2022: Amgen dials up biosimilar ambitions, with at least $4B in expected sales by 2030
JPM 2022: Amgen dials up biosimilar ambitions, with at least $4B in expected sales by 2030 fkansteiner Tue, 01/11/2022 - 14:29